Jason Williams, DO
Family Medicine · El Dorado, KSNPI 1760420012
Payments from drug & device makers
Across 102 payments — averaging $18.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$530
- Novo Nordisk$230
- Amgen$154
- Abbott$125
- Lilly USA, LLC$123
- E.r. Squibb & Sons, L.L.C.$87
- plus $606 from 17 others
What the payments were for
- Food & beverage$1,854100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 29 | $530 |
| Novo Nordisk | 13 | $230 |
| Amgen | 9 | $154 |
| Abbott | 6 | $125 |
| Lilly USA, LLC | 8 | $123 |
| E.r. Squibb & Sons, L.L.C. | 3 | $87 |
| GSK | 5 | $80 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $68 |
| Johnson & Johnson | 4 | $65 |
| AbbVie | 3 | $61 |
| Pfizer | 4 | $56 |
| Phathom Pharmaceuticals, Inc. | 3 | $43 |
| Medtronic | 1 | $27 |
| Bayer | 2 | $26 |
| Sanofi Pasteur Inc. | 1 | $23 |
| Exact Sciences | 1 | $22 |
| Vertex | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Baxter Healthcare | 1 | $20 |
| Antares Pharma, Inc. | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $16 |
How this compares
$1,854 in reported general payments places this provider in the 70th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 112 | $92,504 |
| OzempicSemaglutide | 51 | $63,485 |
| XareltoRivaroxaban | 32 | $32,067 |
| Tresiba Flextouch U-200Insulin Degludec | 30 | $26,401 |
| FarxigaDapagliflozin Propanediol | 21 | $20,380 |
| JanuviaSitagliptin Phosphate | 15 | $19,201 |
| MounjaroTirzepatide | 17 | $18,202 |
| JardianceEmpagliflozin | 20 | $16,152 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $6,065 |
| Potassium Chloride | 245 | $4,013 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 20 | $3,754 |
| TresibaInsulin Degludec | 12 | $3,662 |
| Gabapentin | 148 | $3,074 |
| Fluticasone Propionate HfaFluticasone Propionate | 11 | $2,616 |
| Labetalol Hcl | 87 | $2,483 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $56 | $92,504112 claims |
| Novo NordiskOzempic, Tresiba | $230 | $67,14763 claims |
| Johnson & JohnsonXarelto | $65 | $32,06732 claims |
| AstraZenecaFarxiga | $530 | $20,38021 claims |
| Lilly USA, LLCMounjaro | $123 | $18,20217 claims |
| AbbVieSynthroid | $61 | $1,82637 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in El Dorado
- Crystal FaudereEl Dorado$1.5M
- Diane NightengaleEl Dorado$14K
- Terry PolingWichita$24.2M
- Richard GloverNewton$19.6M
- Daniel DickersonLenexa$13.6M
- Patrick YaoOlathe$11.7M
- Michael RauschAugusta$8.1M
- Terry KleinWichita$5.9M
- Richard EgelhofWichita$4.1M
- Thomas KleinWichita$3.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.